New insider activity at Adaptive Biotechnologies ( (ADPT) ) has taken place on March 18, 2025.
Michelle Burris, the CFO, SVP of Finance, and Treasurer of Adaptive Biotechnologies, has recently sold 36,291 shares of the company’s stock. This transaction amounted to a total value of $260,932.
Recent Updates on ADPT stock
Adaptive Biotechnologies has seen its stock price targets raised by Piper Sandler and Scotiabank, driven by strong quarterly results and promising future prospects. Piper Sandler increased the price target from $7 to $11, maintaining an Overweight rating, following the company’s latest earnings report. Scotiabank also raised its price target from $10 to $12, citing the company’s stable performance and strategic guidance. Additionally, the launch of an upgraded version of the clonoSEQ assay for measurable residual disease detection in diffuse large B-cell lymphoma has contributed to positive sentiment, with the assay demonstrating significant improvements in sensitivity and prognostic value.
More about Adaptive Biotechnologies
YTD Price Performance: 17.61%
Average Trading Volume: 1,595,851
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.08B